BOOSTER – Multicenter, Open Label, Randomized Control Phase III Trial Comparing the Efficacy and Safety of Two Rituximab Regimens in Maintenance Therapy for Relapsing Nephrotic Syndrome Due to Podocytopathies in Adults.

Idiopathic steroid-sensitive nephrotic syndrome

Time from randomization to first relapse of nephrotic syndrome (non-inferiority hypothesis).

Time from randomization to first relapse of nephrotic syndrome (superiority hypothesis)., Percentage of nephrotic syndrome relapse within 24 months., Cumulative dose of glucocorticoids administered within 24 months of randomization., Absolute values and differences from the entry assessment in the number of points obtained in the EQ-index (EQ-index) and analog scale (EQ-VAS) according to the EQ-5D-5L questionnaire at 24 months after randomization., Severe adverse event rate., Rate of adverse events of special interest.

No related papers found yet.

Poland